Thiakis gets L10M investment for obesity therapy
Thiakis Ltd, a UK based biopharmaceutical company focused on the development of peptide hormones for the treatment of obesity, says it has completed a L10.0 million ($18.9 million) Series A financing round. The investment syndicate was jointly led by Novo A/S and Advent Venture Partners, both leading international life science venture capital groups. Martin Edwards of Novo A/S and Raj Parekh of Advent Venture Partners will join the Board of Thiakis.
The UK firm says it will use the funds to develop its oxyntomodulin peptides for the treatment of obesity through preclinical development and into the clinic and to expand its pipeline of development projects.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze